stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Shares outstanding
BeOne Medicines Ltd. - Sponsored ADR's shares outstanding at the end of fiscal 2025 was $113.4M, up 7.75% from $105.3M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $115.8M. Over the past ten years it has ranged from $8.5M (fiscal 2015) to $113.4M (fiscal 2025) — the current reading is the highest in ten years. BeOne Medicines Ltd. - Sponsored ADR ranks 116th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $113.4M | 7.75% |
| FY2024 | $105.3M | 0.86% |
| FY2023 | $104.4M | 1.22% |
| FY2022 | $103.1M | 11.15% |
| FY2021 | $92.8M | 11.16% |
| FY2020 | $83.5M | 38.99% |
| FY2019 | $60.1M | 8.32% |
| FY2018 | $55.4M | 32.69% |
| FY2017 | $41.8M | 34.58% |
| FY2016 | $31.0M | 264.95% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $115.8M | 0.02% |
| Mar 2026 | $115.8M | 2.05% |
| Dec 2025 | $113.4M | (0.94%) |
| Sep 2025 | $114.5M | 1.74% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| RPRX Royalty Pharma PLC compare | $557.0M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| RVMD Revolution Medicines, Inc. compare | $214.9M |
| INCY Incyte Corporation compare | $203.2M |
| ONC BeOne Medicines Ltd. - Sponsored ADR | $115.8M |
| ARGX argenex SE compare | $64.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement